After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The company sans CEO Scangos needs to do some type of deal in the coming months.
Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.
A sharp selloff in crude kept stocks mostly in the red, though optimism ahead of Friday's jobs reports kept losses to a minimum on Thursday.
The company's shares were up nearly 2% in after hours trading.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.